WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced completion of enrollment in the INVICTUS pivotal Phase 3 clinical study evaluating the safety and efficacy of DCC-2618, a broad-spectrum KIT and PDGFRα inhibitor, in fourth-line and fourth-line-plus gastrointestinal stromal tumor (GIST) patients.
“We are very pleased to have completed enrollment in the INVICTUS pivotal Phase 3 study, initiated in January 2018. We expect to report top-line data from this randomized, double-blind study in mid-2019 and, if successful, we believe the results would support a New Drug Application (NDA) for full approval in fourth-line and fourth-line-plus GIST patients,” said Michael D. Taylor, Ph.D., President and Chief Executive Officer of Deciphera. “Currently there are no treatments approved for fourth-line and fourth-line-plus GIST and we are grateful to those patients who participated in our study and to the GIST community for its support. In addition, we look forward to initiating later this year a second pivotal Phase 3 study, the INTRIGUE study, in second-line GIST patients who have progressed or are intolerant to front-line therapy with imatinib, including those with any KIT or PDGFRα mutation.”
On October 19, 2018, Deciphera presented updated data from its ongoing
Phase 1 clinical trial of DCC-2618 in patients with GIST at the European
Society of Medical Oncology (ESMO) 2018 Congress in Munich, Germany.
https://investors.deciphera.com/news-releases/news-release-details/deciphera-pharmaceuticals-reports-updated-preliminary-phase-1.
About the INVICTUS Phase 3 Study
The INVICTUS Phase 3
clinical study is a randomized, double-blind, placebo-controlled,
international, multicenter trial to evaluate the safety, tolerability,
and efficacy of DCC-2618 compared to placebo in patients with advanced
GIST whose previous therapies have included imatinib, sunitinib, and
regorafenib. This study was designed to provide the definitive evidence
of clinical benefit in fourth-line and fourth-line-plus GIST patients
that would be required to secure a full regulatory approval. Patients
were randomized 2:1 to either 150 mg of DCC-2618 or placebo once daily.
The primary efficacy endpoint is median progression-free survival (PFS)
as determined by independent radiologic review using modified Response
Evaluation Criteria in Solid Tumors (RECIST). Secondary endpoints as
determined by independent radiologic review using modified RECIST
include Objective Response Rate (ORR), Time to Tumor Progression (TTP),
and Overall Survival (OS). See www.clinicaltrials.gov
for further information (NCT03353753).
About DCC-2618
DCC-2618 is an investigational KIT and PDGFRα
kinase switch control inhibitor in clinical development for the
treatment of KIT and/or PDGFRα-driven cancers, including
gastrointestinal stromal tumors, or GIST, systemic mastocytosis, or SM,
and other cancers. DCC-2618 was specifically designed to improve the
treatment of GIST patients by inhibiting a broad spectrum of mutations
in KIT and PDGFRα. DCC-2618 is a KIT and PDGFRα inhibitor that blocks
initiating and secondary KIT mutations in exons 9, 11, 13, 14, 17, and
18, involved in GIST as well as the primary D816V exon 17 mutation
involved in SM. DCC-2618 also inhibits primary PDGFRα mutations in exons
12, 14 and 18, including the exon 18 D842V mutation, involved in a
subset of GIST.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals is
a clinical-stage biopharmaceutical company focused on improving the
lives of cancer patients by tackling key mechanisms of drug resistance
that limit the rate and/or durability of response to existing cancer
therapies. Our small molecule drug candidates are directed against an
important family of enzymes called kinases, known to be directly
involved in the growth and spread of many cancers. We use our deep
understanding of kinase biology together with a proprietary chemistry
library to purposefully design compounds that maintain kinases in a
“switched off” or inactivated conformation. These investigational
therapies comprise tumor-targeted agents designed to address therapeutic
resistance causing mutations and immuno-targeted agents designed to
control the activation of immunokinases that suppress critical immune
system regulators, such as macrophages. We have used our platform to
develop a diverse pipeline of tumor-targeted and immuno-targeted drug
candidates designed to improve outcomes for patients with cancer by
improving the quality, rate and/or durability of their responses to
treatment.
Availability of Other Information About Deciphera Pharmaceuticals
Investors
and others should note that Deciphera Pharmaceuticals communicates with
its investors and the public using its company website (www.deciphera.com),
including but not limited to investor presentations and scientific
presentations, Securities and Exchange Commission filings, press
releases, public conference calls and webcasts. The information that
Deciphera Pharmaceuticals posts on these channels and websites could be
deemed to be material information. As a result, Deciphera
Pharmaceuticals encourages investors, the media and others interested in
Deciphera Pharmaceuticals to review the information that it posts on
these channels, including Deciphera Pharmaceuticals’ investor relations
website, on a regular basis. This list of channels may be updated from
time to time on Deciphera Pharmaceuticals' investor relations website
and may include other social media channels than the ones described
above. The contents of Deciphera Pharmaceuticals' website or these
channels, or any other website that may be accessed from its website or
these channels, shall not be deemed incorporated by reference in any
filing under the Securities Act of 1933, as amended.
Cautionary Note Regarding Forward-Looking Statements
This
press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, as amended,
including, without limitation, statements regarding our expectations
regarding timing of reporting top-line data from our INVICTUS pivotal
Phase 3 study, our expectations regarding an NDA for full approval in
fourth-line-plus GIST patients, the planned initiation of our second
pivotal Phase 3 INTRIGUE study in second-line GIST patients who have
progressed or are intolerant to front-line therapy with imatinib, the
potential for DCC-2618 to treat cancers such as GIST, our commercial
readiness planning, and other business strategies. The words “may,”
“will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,”
“intend,” “believe,” “estimate,” “predict,” “project,” “potential,”
“continue,” “target” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking statements
contain these identifying words. Any forward-looking statements in this
press release are based on management’s current expectations and beliefs
and are subject to a number of risks, uncertainties and important
factors that may cause actual events or results to differ materially
from those expressed or implied by any forward-looking statements
contained in this press release, including, without limitation, risks
and uncertainties related to the delay of any current or planned
clinical studies or the development of our drug candidates, including
DCC-2618, rebastinib, and DCC-3014, our advancement of multiple
early-stage and later-stage efforts, our ability to successfully
demonstrate the efficacy and safety of our drug candidates including in
later-stage studies, the preclinical and clinical results for our drug
candidates, which may not support further development of such drug
candidates, our efforts to scale up drug product manufacturing, our
ability to implement commercial readiness, actions of regulatory
agencies, any or all of which may affect the initiation, timing and
progress of clinical studies and other risks identified in our SEC
filings, including our Quarterly Report on Form 10-Q for the quarter
ended September 30, 2018, and subsequent filings with the SEC. We
caution you not to place undue reliance on any forward-looking
statements, which speak only as of the date they are made. We disclaim
any obligation to publicly update or revise any such statements to
reflect any change in expectations or in events, conditions or
circumstances on which any such statements may be based, or that may
affect the likelihood that actual results will differ from those set
forth in the forward-looking statements. Any forward-looking statements
contained in this press release represent our views only as of the date
hereof and should not be relied upon as representing its views as of any
subsequent date. We explicitly disclaim any obligation to update any
forward-looking statements.
